[The reversion of multidrug resistance in tumour cell line MCF-7/Adr by ribozyme].
To construct a specific hammerhead ribozyme possessing catalytic activity that cleaves the mdr1 mRNA for reversing the resistant phenotype in tumour cell line. A DNA sequence encoding the ribozyme gene was incorporated into a eukaryotic expression vector (pH beta Apr-1 neu) and transfected into the human breast carcinoma cell line MCF-7/Adr, which is resistant to adriamycin and expresses the MDR phenotype. The ribozyme was stably expressed in the cell line, and decreased the level of mdr1 mRNA expression by 83.5%. The ribozyme inhibited the formation of P-glycoprotein and reduced the cell's resistance to adriamycin. The resistant cells were 1,000-fold more resistant than the parental cell line (MCF-7), whereas those cell clones that showed ribozyme expression were only 6-fold more resistant than the parental cell line.